Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 3Sarcoma, Myeloid 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Promyelocytic, Acute 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 19Vincristine 14Methotrexate 13blinatumomab 12Prednisone 12Cytarabine 12merphos 11Specimen Handling 10Mercaptopurine 10prednylidene 9pegaspargase 9deltacortene 9azathiopurine 9N,N-dicyclohexyl-isoborneol-10-sulfonamide 9Dexamethasone 9Leucovorin 8Doxorubicin 8Biopsy 8dexamethasone acetate 7dexamethasone 21-phosphate 7auricularum 7Etoposide 7Calcium Dobesilate 7Thioguanine 6Spinal Puncture 6Daunorubicin 6Asparaginase 6venetoclax 5fludarabine 5calaspargase pegol 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Burkitt Lymphoma × Mitoxantrone × 30 days × Clear all
NCT02101853 2026-06-03

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
669 enrolled 14 charts
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡